Sandoz Group AG (SDZNY)
- Previous Close
48.12 - Open
48.67 - Bid 48.75 x 40000
- Ask 48.80 x 40000
- Day's Range
48.43 - 48.80 - 52 Week Range
34.50 - 49.81 - Volume
3,339 - Avg. Volume
37,957 - Market Cap (intraday)
21.018B - Beta (5Y Monthly) --
- PE Ratio (TTM)
∞ - EPS (TTM)
0.00 - Earnings Date Aug 7, 2025
- Forward Dividend & Yield 0.67 (1.40%)
- Ex-Dividend Date Apr 22, 2025
- 1y Target Est
--
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
www.sandoz.com22,049
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SDZNY
View More
Performance Overview: SDZNY
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SDZNY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SDZNY
View MoreValuation Measures
Market Cap
20.65B
Enterprise Value
24.31B
Trailing P/E
--
Forward P/E
12.94
PEG Ratio (5yr expected)
0.13
Price/Sales (ttm)
2.01
Price/Book (mrq)
2.54
Enterprise Value/Revenue
2.34
Enterprise Value/EBITDA
32.77
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
0.98%
Return on Equity (ttm)
0.01%
Revenue (ttm)
10.38B
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
0.00
Balance Sheet and Cash Flow
Total Cash (mrq)
1.19B
Total Debt/Equity (mrq)
59.64%
Levered Free Cash Flow (ttm)
632M